Research Roundup

light bulb with gears
Debbie Rigby takes a look at the latest in research news  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT) A 24-week randomised controlled, comparative effectiveness trial comparing extended-release naltrexone, an opioid antagonist, and sublingual buprenorphine-naloxone, a partial opioid agonist has concluded these medicines indicated for opioid dependence are equally safe and

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Setting the agenda
Next Mind-bending drugs and devices: can they make us smarter?